# Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

> **NCT06711523** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Kexing Biopharm Co., Ltd.** · enrollment: 250 (estimated)

## Conditions studied

- Neutropenia, Chemotherapy-Induced Febrile
- Breast Neoplasm Female

## Interventions

- **DRUG:** PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)
- **DRUG:** PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)

## Key facts

- **NCT ID:** NCT06711523
- **Lead sponsor:** Kexing Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711523, "Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06711523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*